Clinical Report: FDA Clears Avulux Migraine Lenses
Overview
The FDA has granted De Novo marketing authorization for Avulux's precision light-filtering lenses, aimed at managing light sensitivity in patients with episodic migraine. These lenses block specific wavelengths of light while allowing the rest of the visible spectrum to pass through.
Background
Migraine is a prevalent condition affecting millions, with photophobia being a common and debilitating symptom. Traditional management focuses on pharmacologic therapies, but the introduction of optical devices like Avulux lenses provides a novel adjunctive option for patients experiencing light sensitivity.
Data Highlights
The Avulux lenses are indicated for patients aged 12 years and older with episodic migraine and have been dispensed to over 50,000 users through more than 1,400 eye care providers across the US and Canada.
Key Findings
- The lenses block light at 480 nm (high-blue) and 590 nm (red/amber) while allowing other visible light to pass.
- Up to 90% of migraine patients experience light sensitivity, with light triggering up to 60% of migraine attacks.
- The lenses are designed to complement existing migraine treatments rather than replace them.
- Avulux lenses are available over-the-counter and can be made with or without prescription correction.
- The FDA's De Novo authorization creates a new classification for light attenuation lenses specifically for migraine-associated light sensitivity.
Clinical Implications
Healthcare providers can consider Avulux lenses for patients with episodic migraine who experience significant light sensitivity.
Conclusion
The FDA's authorization of Avulux lenses provides a new tool for managing light sensitivity associated with migraine.
Related Resources & Content
- Optometric Management, FDA Grants Avulux De Novo Authorization Recommendations, 2026 -- FDA Grants Avulux De Novo Authorization
- Optometric Management, Seeing the Light, 2024 -- Seeing the Light
- Optometric Management, CONTACT LENS FOCUS: Relieving migraines Recommendations, 2024 -- CONTACT LENS FOCUS: Relieving migraines
- FDA, Regulatory context as of September 2026 -- FDA De Novo Marketing Authorization
- Neurology, Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations -- Pharmacologic Treatment for Migraine Prevention
- optometric management — CONTACT LENS FOCUS: Relieving migraines
- Correspondence Generator (CorGen)
- Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations | Neurology
- Targeting the intrinsically photosensitive retinal ganglion cell to reduce headache pain and light sensitivity in migraine: A randomized double-blind trial - Journal of Clinical Neuroscience
Based on findings from:
FDA Clears Avulux Migraine Lenses
The Ophthalmologist, 2026.
https://theophthalmologist.com/issues/2026/articles/september/fda-clears-avulux-migraine-lenses/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
